Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 69-74 , February 2010

Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis

  • Davide Mauri

      Affiliations

    • Department of Medical Oncology, General Hospital of Lamia, Lamia, Greece
    • Panhellenic Association for Continual Medical Research (PACMeR), Greece
    • Corresponding Author InformationCorresponding author. Address: Department of Medical Oncology, General Hospital of Lamia, Daravelia 23, Roditsa-Lamias, TK 35100, Lamia, Greece. Tel.: +30 694 55 62 573.
    • ,
  • Konstantinos Kamposioras

      Affiliations

    • Panhellenic Association for Continual Medical Research (PACMeR), Greece
    • ,
  • Lamprini Tsali

      Affiliations

    • Department of Medical Oncology, General Hospital of Lamia, Lamia, Greece
    • Panhellenic Association for Continual Medical Research (PACMeR), Greece
    • ,
  • Magdalini Bristianou

      Affiliations

    • Department of Medical Oncology, General Hospital of Lamia, Lamia, Greece
    • Panhellenic Association for Continual Medical Research (PACMeR), Greece
    • ,
  • Antonis Valachis

      Affiliations

    • Department of Medical Oncology, General Hospital of Lamia, Lamia, Greece
    • Panhellenic Association for Continual Medical Research (PACMeR), Greece
    • ,
  • Ioanna Karathanasi

      Affiliations

    • Panhellenic Association for Continual Medical Research (PACMeR), Greece
    • ,
  • Christos Georgiou

      Affiliations

    • Department of Medical Oncology, General Hospital of Lamia, Lamia, Greece
    • ,
  • Nikolaos P. Polyzos

      Affiliations

    • Panhellenic Association for Continual Medical Research (PACMeR), Greece
    • Department of Obstetric and Gynecology, University Hospital of Larisa, Greece

Received 27 August 2009 ,Revised 26 October 2009 ,Accepted 27 October 2009.

References 

  1. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP. Multiple treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst. 2008;100(24):1780–1791
  2. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:1800–1808
  3. Hainsworth JD, Burris HA, Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998;16:2164–2168
  4. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol. 1994;12:1458–1467
  5. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000;18:1212–1219
  6. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16
  7. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188Sep
  8. Cochran W. The combination of estimates from different experiments. Biometrics. 1954;10:101–129
  9. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558
  10. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  11. Rivera E, Mejia JA, Arun BK, Adinin RB, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008;112(7):1455–1461
  12. Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2004;15(9):1358–1365
  13. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26(10):1642–1649
  14. Fountzilas G, Dafni U, Dimopoulos MA, et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat. 2009;115(1):87–99
  15. Frasci G, D’Aiuto G, Comella P, et al. Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study. Br J Cancer. 2006;95(8):1005–1012
  16. Khoo KS, Manzoor Zaidi SH, Srimuninnimit V, et al. Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study. Eur J Cancer. 2006;42(12):1797–1806
  17. Sedky L, El-Dine IS, Hazme B, Samir Motawe S, Fahmi R. Weekly docetaxel vs every 3-week in advanced breast cancer: results of a pilot comparative study. Proc Am Soc Clin Oncol. 2002;21:[abstr 2013]
  18. Gradishar WJ, Krasnojon D, Cheporov S, et al. Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer. Eur J Cancer. 2007;5(Suppl. 4):215;abstr P#2106
  19. Frasci G, D’Aiuto G, Comella P, et al. Weekly cisplatin–epirubicin–paclitaxel with G-CSF support (PET) vs. triweekly epirubicin–paclitaxel (ET) in metastatic breast cancer (MBC). J Clin Oncol. 2005;23(16S, June 1 Suppl.):580
  20. Sikov WM, Akerley W, Kahanic S, et al. Multicenter, 3-arm randomized study of high-dose weekly paclitaxel (HDWP) versus standard-dose weekly paclitaxel (SDWP) for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol. 2002;21:[abstr 134]
  21. Willemse P, Munck L, Creemers GJ, et al. A phase III study on the efficacy and safety of docetaxel, every three weeks or as a weekly regimen in patients with metastatic breast cancer. Breast Cancer Res Treat. 2007;106(Suppl. 1):S70;[abstract 1083]
  22. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009;27(22):3611–3619
  23. Saad ED, Katz A. Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. Ann Oncol. 2009;20(3):460–464
  24. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof. 2002;25:76–97
  25. Clarke M, Stewart L, Pignon JP, Bijnens L. Individual patient data metanalysis in cancer. Br J Cancer. 1998;77:2036–2044
  26. Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancet. 1998;351:123–127

PII: S0305-7372(09)00159-5

doi: 10.1016/j.ctrv.2009.10.006

Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 69-74 , February 2010

Article Tools

* Image Usage & Resolution